Please assess the completion status of the following clinical trial:

Trial Title: C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HAE~* Normal C1q level~Exclusion Criteria:~* Low C1q level~* B-cell malignancy~* Presence of anti-C1INH autoantibody~* History of allergic reaction to C1INH or other blood products~* Narcotic addiction~* Current participation in any other investigational drug study or within the past 30 days~* Participation in a C1 esterase inhibitor trial, or received blood or a blood product in the past 90 days~* Pregnancy or lactation~* Any clinically significant medical condition, such as renal failure, that in the opinion of the investigator would interfere with the subject's ability to participate in the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C1INH-nf (Type: EXPERIMENTAL): 1,000 Units (U) of C1INH-nf administered intravenously (IV). If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo (saline) administered IV. If there was no response to treatment 60 minutes after the first dose, a second placebo (saline) dose could be administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).